I. Blasco

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

J. Baselga, K. Venkatakrishnan, J. Tabernero, 2012, Clinical Cancer Research.

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

I. Chirivella, F. Papaccio, A. Cervantes, 2021, British Journal of Cancer.

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

Arijit Chakravarty, Hua Liu, Jeffrey Ecsedy, 2010, Molecular Cancer Therapeutics.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

A. Cervantes, K. Jordan, S. Roselló, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

A. Cervantes, K. Jordan, S. Roselló, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

F. Pérez-Miralles, I. Blasco, J. L. P. Andrés, 2014 .

Study of the Selective Aurora A Kinase Inhibitor 8054 in Patients with Advanced Solid Tumors : Safety , Ther rmacokinetics , and Pharmacodynamics

J. Baselga, J. Tabernero, H. Fingert, 2010 .

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

A. Cervantes, K. Jordan, S. Roselló, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

S. Roselló, I. Blasco, L. G. Fabregat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.